MedPath

Nicorandil

Generic Name
Nicorandil
Drug Type
Small Molecule
Chemical Formula
C8H9N3O4
CAS Number
65141-46-0
Unique Ingredient Identifier
260456HAM0
Background

Nicorandil is an orally efficacious vasodilatory drug and antianginal agent marketed in the UK, Australia, most of Europe, India, Philippines, Japan, South Korea, and Taiwan. It is not an approved drug by FDA. It is a niacinamide derivative that induces vasodilation of arterioles and large coronary arteries by activating potassium channels. It is often used for patients with angina who remain symptomatic despite optimal treatment with other antianginal drugs . Nicorandil is a dual-action potassium channel opener that relaxes vascular smooth muscle through membrane hyperpolarization via increased transmembrane potassium conductance and increased intracellular concentration of cyclic GMP. It is shown to dilate normal and stenotic coronary arteries and reduces both ventricular preload and afterload .

Indication

Indicated for the prevention and treatment of chronic stable angina pectoris and reduction in the risk of acute coronary syndromes.

Associated Conditions
Angina Pectoris

Effects of Nicorandil on Microvascular Dysfunction in Patients with STEMI Undergoing Primary PCI

Phase 4
Not yet recruiting
Conditions
STEMI - ST-segment Elevation Myocardial Infarction
Interventions
Drug: Saline (NaCl 0,9 %) (placebo)
First Posted Date
2025-01-22
Last Posted Date
2025-01-22
Lead Sponsor
China National Center for Cardiovascular Diseases
Target Recruit Count
170
Registration Number
NCT06787430

Nephroprotective Effect of Nicorandil in Type 2 Diabetes Mellitus

Phase 3
Recruiting
Conditions
Type2 Diabetes Mellitus
Interventions
First Posted Date
2024-05-28
Last Posted Date
2024-05-28
Lead Sponsor
Tanta University
Target Recruit Count
46
Registration Number
NCT06430125
Locations
🇪🇬

Tanta University, Tanta, EL Gharbia, Egypt

Effect of Nicorandil in Type 2 Diabetic Obese Patients

Phase 2
Recruiting
Conditions
Diabetes Mellitus, Type 2
Interventions
First Posted Date
2024-05-21
Last Posted Date
2024-05-23
Lead Sponsor
Tanta University
Target Recruit Count
46
Registration Number
NCT06423729
Locations
🇪🇬

Faculty of Pharmacy, Tanta University, Tanta, Egypt

Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer

Phase 1
Active, not recruiting
Conditions
Colorectal Cancer
Non-Small Cell Lung Cancer
Interventions
First Posted Date
2023-07-20
Last Posted Date
2025-02-27
Lead Sponsor
Genentech, Inc.
Target Recruit Count
172
Registration Number
NCT05954871
Locations
🇺🇸

Yale Cancer Center, New Haven, Connecticut, United States

🇺🇸

Christiana Care Health System, Newark, Delaware, United States

🇺🇸

SCRI Oncology Partners, Nashville, Tennessee, United States

and more 8 locations

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Phase 1
Active, not recruiting
Conditions
Advanced Solid Tumors
Metastatic Solid Tumors
Interventions
First Posted Date
2022-08-04
Last Posted Date
2025-03-25
Lead Sponsor
Genentech, Inc.
Target Recruit Count
232
Registration Number
NCT05487235
Locations
🇦🇷

Sanatorio Allende, Cordoba, Argentina

🇦🇷

Fundacion CORI para la Investigacion y Prevencion del Cancer, La Rioja, Argentina

🇦🇷

Centro Medico IPAM, Rosario, Argentina

and more 23 locations

A Study to Evaluate the Impact of Pre-procedural Intracoronary Nicorandil Injection to PREVENT ReductioN of DecREased TIMI FLOW in Patients Who Undergoing Percutaneous Coronary Intervention for the Coronary Artery Disease

Phase 4
Recruiting
Conditions
No-Reflow Phenomenon
Coronary Artery Disease
Percutaneous Coronary Intervention
Interventions
First Posted Date
2022-06-22
Last Posted Date
2024-10-10
Lead Sponsor
Korea University Anam Hospital
Target Recruit Count
460
Registration Number
NCT05427786
Locations
🇰🇷

Korea University Anam Hospital, Seoul, Korea, Republic of

Intracoronary of Nicorandil and Verapamil to Reduce the Occurrence of Periprocedural Myocardial Injury

Phase 2
Conditions
Coronary Artery Disease
Interventions
Drug: Saline
First Posted Date
2022-06-01
Last Posted Date
2022-06-01
Lead Sponsor
The First Affiliated Hospital of Zhejiang Chinese Medical University
Target Recruit Count
150
Registration Number
NCT05399576
Locations
🇨🇳

yuangang Qiu, Hangzhou, Zhejiang, China

The Effect of Nicorandil on Left Ventricular Myocardial Strain in Patients With Coronary Chronic Total Occlusion

Phase 4
Completed
Conditions
Coronary Artery Disease
Interventions
First Posted Date
2021-10-21
Last Posted Date
2021-10-21
Lead Sponsor
Peking University Third Hospital
Target Recruit Count
61
Registration Number
NCT05087797
Locations
🇨🇳

Peking University Third Hospital, Beijing, Beijing, China

Effect of Nicorandil on Cardiac Sympathetic Nerve for the Patients of Acute ST Segment Elevation Myocardial Infarction

Phase 4
Conditions
Coronary Heart Disease
Interventions
Drug: Placebo(normal saline)
First Posted Date
2021-04-01
Last Posted Date
2021-04-01
Lead Sponsor
Xuzhou Central Hospital
Target Recruit Count
80
Registration Number
NCT04826497

Clinical Efficacy and SAfety of Intravenous Infusion of Nicorandil During Primary Percutaneous Coronary Intervention

Phase 4
Completed
Conditions
ST Elevation Myocardial Infarction
Percutaneous Coronary Intervention
Interventions
Drug: Placebo
First Posted Date
2020-12-11
Last Posted Date
2025-03-11
Lead Sponsor
Fudan University
Target Recruit Count
1500
Registration Number
NCT04665648
Locations
🇨🇳

Zhongshan Hospital, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath